Launch of Generic Xarelto (Rivaroxaban) Tablets

Generic Xarelto (Rivaroxaban) has recently been approved by the FDA and released in 2.5 mg tablets.

Rivaroxaban is an anticoagulant that belongs to a class of medications called factor Xa inhibitors and are indicated to reduce the risk of major cardiovascular events in adult patients with CAD (Coronary Artery Disease). Rivaroxaban is also indicated to reduce the risk of major thrombotic vascular events in adult patients with PAD (Peripheral Artery Disease), including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD.

The approval and release of the first generics of Rivaroxaban 2.5 mg tablets will provide more treatment options for patients who rely on anticoagulant medications.

Xarelto is also available in 10 mg, 15 mg and 20 mg tablets, and as an oral suspension. It is uncertain when these strengths will be available in generic.